10-K: TELA Bio Reports 16% Revenue Growth, $38.8M Net Loss in 2025

TELA Bio, a medical technology company, reported a 16% increase in revenue to $80.3 million for 2025, alongside a net loss of $38.8 million, as it expands its soft-tissue reconstruction product portfolio.

Summary

• Revenue for the year ended December 31, 2025, increased by 16% to $80.3 million, up from $69.3 million in 2024.
• The net loss for 2025 was $38.8 million, a 3% increase from the $37.8 million net loss in 2024.
• The accumulated deficit as of December 31, 2025, reached $397.6 million.
• OviTex unit sales volume increased by 22% to 22,063 units in 2025, compared to 18,121 units in 2024.
• OviTex PRS unit sales volume increased by 12% to 5,189 units in 2025, compared to 4,645 units in 2023.
• The company launched OviTex IHR Reinforced Tissue Matrix in the U.S. in April 2024 and in European markets in June 2025.
• Larger configurations of OviTex LPR were launched in February 2023, and larger sizes of OviTex PRS were launched in March 2025.
• FDA approval for an investigational device exemption (IDE) application for OviTex PRS in implant-based breast reconstruction was received in October 2024.
• A distribution agreement for LIQUIFIX Hernia Mesh Fixation Devices was entered into in September 2023, with a full U.S. commercial launch in March 2024.
• Distribution rights for NIVIS Fibrillar Collagen Pack were sold to MiMedx Group, Inc. in March 2024 for an initial $5.0 million payment and potential future payments of $3.0 million to $7.0 million.
• Cash and cash equivalents stood at $50.8 million as of December 31, 2025.
• The company had $60.0 million of indebtedness outstanding under a new credit facility with Perceptive Credit Holdings V, LP, maturing in November 2030.
• A deficiency letter was received from Nasdaq on March 17, 2026, for failing to meet the minimum $1.00 bid price requirement for continued listing.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While revenue growth and product expansion are positive, the continued net losses, growing accumulated deficit, and the Nasdaq deficiency letter raise significant concerns about financial stability and market perception.

Positives

• Achieved strong revenue growth of 16% to $80.3 million in 2025, driven by new customers and deeper penetration in existing accounts.
• Experienced significant unit sales volume increases for both OviTex (22%) and OviTex PRS (12%) products.
• Successfully launched new product configurations, including OviTex IHR in the U.S. and Europe, and larger sizes of OviTex LPR and OviTex PRS.
• The BRAVO study for OviTex in ventral hernia repair showed a low 24-month recurrence rate of 2.6% and statistically significant improvements in patient quality of life, particularly in high-risk patients.
• Received FDA approval for an investigational device exemption (IDE) for OviTex PRS in implant-based breast reconstruction, paving the way for a new indication.
• Secured a strategic distribution agreement for LIQUIFIX Hernia Mesh Fixation Devices, expanding the product portfolio.
• Realized a $7.6 million gain from the sale of NIVIS distribution rights to MiMedx Group, Inc.
• Negotiated a new $70.0 million credit facility with Perceptive Credit Holdings V, LP, extending debt maturity to November 2030 and providing additional capital access.
• Gross margin improved to 68% in 2025 from 67% in 2024, primarily due to lower excess and obsolete inventory adjustments as a percentage of revenue.

Negatives

• Continued to incur net losses, with a 3% increase to $38.8 million in 2025, indicating ongoing unprofitability.
• The accumulated deficit grew to $397.6 million as of December 31, 2025, reflecting substantial historical losses.
• Received a Nasdaq deficiency letter on March 17, 2026, for failing to meet the minimum $1.00 bid price requirement, posing a risk of delisting.
• Experienced a decrease in average selling prices for hernia products due to a shift in product mix towards smaller-sized units.
• Incurred a $0.9 million loss on the extinguishment of debt related to the repayment of the former MidCap credit facility.
• Macroeconomic conditions, including financial strain on hospital systems, cybersecurity events impacting customers, supply chain disruptions, and inflationary pressures, continue to negatively impact business operations and prospects.
• The company remains highly dependent on sales of its OviTex products, which accounted for 64% of total revenue in 2025, making it vulnerable to market shifts for this product line.
• Reliance on Aroa Biosurgery Ltd. as the exclusive contract manufacturer and supplier introduces risks of production delays or quality control issues.

Risks

• Incurred significant operating losses since inception, expects to continue incurring losses, and may not achieve or sustain profitability.
• Indebtedness of $60.0 million may limit operational flexibility and adversely affect financial health and competitive position.
• May require substantial additional capital to finance planned operations, which may not be available on acceptable terms or at all, potentially delaying development or commercialization.
• Inability to expand, manage, and maintain direct sales and marketing organizations could prevent generation of anticipated revenue.
• Macroeconomic conditions, including financial strain on hospital systems, cybersecurity events, supply chain disruptions, inflationary pressures, and geopolitical conflicts, may negatively impact business, prospects, results of operations, and financial condition.
• Rising inflation rates could negatively impact revenues and profitability if cost increases cannot be passed on or consumer spending decreases.
• High dependence on the commercial success of OviTex products, which generated the vast majority of revenue.
• Commercial success depends on attaining significant market acceptance, which is not guaranteed, and surgeons may prefer alternative products.
• Misuse or off-label use of products may harm reputation, lead to product liability suits, or result in costly investigations, fines, or sanctions by regulatory bodies.
• Inability to achieve and maintain adequate levels of coverage or reimbursement for products could hinder commercial success.
• Competitors entering into supply contracts that disfavor TELA Bio's products or discourage their use could adversely affect commercial success.
• Long-term growth may depend on the ability to enhance product offerings, and products may become obsolete due to rapid industry changes.
• High dependence on Aroa Biosurgery Ltd. as the exclusive contract manufacturer and supplier, including for FDA clearances for OviTex products, exposes the company to supply disruptions and regulatory compliance risks.
• Potential for development or manufacturing problems, capacity constraints, disruptions, or delays in the production of products.
• Products contain materials derived from animal sources (ovine rumen) and may become subject to additional regulation or supply disruption due to natural disaster or disease.
• Cybersecurity risks, cyber incidents, and technology failures related to internal or vendor systems may adversely affect business operations, compromise confidential information, or damage business relationships.
• May need to license intellectual property from third parties, and such licenses may not be available or on commercially reasonable terms.
• Failure to comply with obligations under license, collaboration, or other agreements could lead to the loss of necessary intellectual property rights.
• Inability to adequately protect intellectual property rights or accusations of infringing on others' intellectual property rights could harm competitive position or incur significant expenses.
• Litigation or other proceedings or third-party claims of intellectual property infringement could require significant time and money, necessitate license agreements, and prevent product sales.
• Inability to protect the confidentiality of trade secrets could harm business and competitive position.
• Products and operations are subject to extensive government regulation and oversight both in the U.S. and internationally.
• May not receive, or may be significantly delayed in receiving, necessary clearances or approvals for future products and modifications, potentially requiring new 510(k) clearances or PMA approvals.
• Products will remain subject to extensive regulatory scrutiny even after obtaining regulatory clearance.
• Changes in guidelines for soft-tissue reconstruction surgery or the standard of care could necessitate product redesign and new marketing authorization from the FDA.
• If products cause or contribute to a death, serious injury, or other adverse medical events, or malfunction, reporting obligations could result in voluntary corrective actions or agency enforcement actions.
• Legislative or regulatory reforms (e.g., QMSR enforcement, overruling of Chevron doctrine, AI Act) may make it more difficult and costly to obtain regulatory clearances or approvals or to manufacture, market, or distribute products.
• Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key personnel or prevent timely development/commercialization of new products.
• U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect the business.
• Relationships with surgeons, patients, and payors in the U.S. are subject to applicable anti-kickback, fraud, and abuse laws and regulations.
• Subject to anti-bribery, anti-corruption, and anti-money laundering laws (e.g., U.S. FCPA, U.K. Bribery Act), violations of which could result in substantial penalties and prosecution.
• Use of new and evolving technologies, such as artificial intelligence, may present cybersecurity, data privacy, IT, intellectual property, regulatory, legal, operational, competitive, and reputational risks.
• Risks related to the collection and use of data (HIPAA, CCPA, GDPR, My Health My Data Act) could result in investigations, inquiries, litigation, fines, legislative and regulatory action, and negative press.
• The Affordable Care Act and any changes in healthcare law may increase the difficulty and cost for commercializing products and affect prices.
• Business involves the use of hazardous materials, and compliance with environmental laws and regulations may be expensive and restrict operations.
• Business may be impacted by political, trade, or regulatory developments in jurisdictions where products are sold, such as tariffs.
• Financial results may fluctuate significantly and may not fully reflect the underlying performance of the business.
• Inability to accurately forecast customer demand for products and manage inventory could materially harm results of operations.
• Reliance on a direct sales force may result in higher fixed costs than competitors and may slow the ability to reduce costs.
• Employees, independent contractors, consultants, commercial partners, distributors, and vendors may engage in misconduct or other improper activities.
• Could be adversely affected by any interruption to the ability to conduct business at the current single location in Malvern, Pennsylvania.
• If the company or its vendors experience a cybersecurity incident, significant disruption, or a compromise of information technology systems, the business could be adversely affected.
• If the company becomes profitable, its ability to use net operating loss carryforwards and other tax attributes to offset future taxable income or taxes may be subject to limitations under Section 382.
• The trading price of the shares of common stock has been and could in the future be highly volatile.
• Failure to comply or regain compliance with the continued listing standards of Nasdaq may result in delisting, negatively impacting stock price and access to capital markets.
• Directors, officers, and principal stockholders have significant voting power and may take actions not in the best interests of other stockholders.
• Provisions in corporate charter documents and under Delaware law could discourage another company from acquiring TELA Bio and may prevent attempts by stockholders to replace or remove current management.
• The exclusive forum provision in the corporate charter documents could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Ability to maintain competitive position depends on the ability to attract and retain senior management and other highly qualified personnel.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

Future Outlook

The company expects to continue incurring operating losses in the near term as it invests in sales, marketing, and research and development initiatives to support growth in existing and new markets. Interest expense is anticipated to increase next year due to the new credit facility's increased borrowing base and interest rate. Management believes existing cash resources will be sufficient to meet capital requirements and fund operations for at least the next 12 months. The company plans to continue expanding product offerings and treatment capabilities, including developing OviTex configurations with longer-acting resorbable polymers and exploring lower-cost, higher-margin polymer-based devices. It also intends to assess additional strategic partnerships to diversify its soft tissue preservation and restoration portfolio.

Management Comments

• We believe that genuine collaboration with surgeons and healthcare providers results in the development of new solutions that empower patient care and addresses unmet needs within the soft tissue reconstruction market.
• We believe we can enhance the productivity of our sales force by improving customer segmentation and targeting, implementing and further refining our proprietary training programs, leveraging support from our medical education and medical affairs functions to drive physician awareness, education and clinical understanding of our products, and utilizing engagement analytics to support further product development and enhancement opportunities.
• We believe based on a review of available literature that the BRAVO recurrence rate is among the lowest reported rate in any published study, including our biologic or resorbable synthetic mesh competitors evaluating product use in this procedural setting and with a similar cohort of high-risk patients.
• We believe our pricing flexibility will continue to drive greater adoption of our products.
• We believe that the average selling prices across our products will provide financial benefits to our customers in addition to improving clinical outcomes.
• We believe our ability to rapidly develop new products and product configurations is attributable to the dynamic product innovation process that we have implemented, the versatility and leveragability of our core technology and the management philosophy behind that process.
• We believe that our current facilities meet our current and future anticipated needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations.
• We believe appropriate office space will be readily available on commercially reasonable terms.
• While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations, or cash flows.
• Based on our current business plan, we believe that our existing cash resources will be sufficient to meet our capital requirements and fund our operations for at least the next 12 months from the issuance of this Annual Report.

Industry Context

StockSavvy.ai notes that TELA Bio operates in a highly competitive medical device industry characterized by rapid change and new product introductions. The company's focus on combining biologic and polymer materials for soft-tissue reconstruction positions it against established players like Bard (Becton, Dickinson and Company) and Allergan (AbbVie) in hernia repair, and Allergan, MTF Biologics, Novadaq, RTI Surgical, Bard, and Integra Lifesciences in plastic and reconstructive surgery. The industry is also facing increasing scrutiny from regulatory bodies regarding product safety, off-label promotion, and data privacy, alongside macroeconomic pressures impacting hospital systems and elective procedures.

Comparison to Industry Standards

• The 24-month recurrence rate of 2.6% from the BRAVO study for OviTex in ventral hernia repair is believed to be among the lowest reported compared to biologic or resorbable synthetic mesh competitors.
• The RICH study, evaluating Strattice (LifeCell Corporation), an industry leader for biological tissue matrices, demonstrated post-operative hernia recurrence rates of 19% and 28% at 12-months and 24-months follow-up, respectively.
• A published study evaluating Phasix (C.R. Bard, Inc.), a market-leading resorbable synthetic mesh, showed a post-operative hernia recurrence rate of 9% at 18-months and 18% at 36-month follow-up.
• OviTex products are priced approximately 20% to 40% lower than leading biologic matrices and resorbable synthetic mesh, offering meaningful cost savings to customers.
• OviTex PRS products are priced below leading biologic matrices, aiming to provide cost savings to customers.
• In non-human primate studies, OviTex products demonstrated a minimal foreign body inflammatory response similar to biologic matrices and less than all synthetic mesh tested.
• Non-human primate comparative studies showed OviTex devices resulted in more rapid tissue integration and revascularization compared to pure biologic matrices, and better functional tissue remodeling compared to permanent and resorbable synthetic mesh.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be subject to other legal proceedings and claims in the ordinary course of business, but management does not expect the ultimate costs to resolve these matters to have a material adverse effect on the company's consolidated financial position, results of operations, or cash flows.
• The medical device industry, including the hernia repair sector, has historically been subject to extensive litigation over product liability claims. Approximately 15,000 cases related to synthetic mesh hernia repairs were outstanding in federal and state courts across the U.S. as of November 2024, with over 40,000 cases settled or dismissed in the prior three-year period, highlighting industry-wide litigation risk.

Related Party Transactions

• The company has an exclusive manufacturing and long-term supply and license agreement (Aroa License) with Aroa Biosurgery Ltd. for OviTex and OviTex PRS products. Under this agreement, Aroa is paid a fixed transfer cost as a percentage of its cost of goods, subject to a true-up adjustment, resulting in an amount equal to 27% of TELA Bio's net sales of OviTex and OviTex PRS products (with exceptions for OviTex IHR).
• The Aroa License grants TELA Bio an exclusive license to certain patent rights and other intellectual property related to Aroa's products and technologies for use in specific indications in North America and Europe.
• TELA Bio made upfront payments totaling $2.3 million and granted 74,316 shares of restricted common stock to Aroa in August 2012. Additional milestone payments aggregating $2.0 million and $4.0 million in revenue-based milestones have been satisfied.
• In connection with the Credit Agreement with Perceptive Credit Holdings V, LP on November 13, 2025, TELA Bio issued warrants to Perceptive to purchase up to 2,000,000 shares of its common stock with an exercise price of $1.11.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises, the risk of delisting from Nasdaq due to non-compliance with the minimum bid price requirement, and continued stock price volatility. No cash dividends are expected in the foreseeable future.
• Employees are eligible for comprehensive benefits, including a 401(k) plan, health and insurance benefits, paid time off, and equity award programs. A new Chief Medical Officer, Dr. Howard Langstein, was appointed, effective March 1, 2026.
• Customers, primarily hospitals and ambulatory surgery centers, benefit from cost-effective soft-tissue reconstruction products and new product configurations. However, they may face financial strain from macroeconomic conditions and cybersecurity events impacting hospital operations.
• Suppliers, particularly Aroa Biosurgery Ltd. as the exclusive manufacturer, maintain a significant revenue-sharing agreement. However, Aroa faces risks related to meeting supply requirements and potential disruptions.
• Creditors, specifically Perceptive Credit Holdings V, LP, have provided a new $70.0 million senior secured term loan facility, with a first lien perfected security interest on substantially all of TELA Bio's assets, and received warrants as consideration.

Next Steps

• Hire additional territory managers and field-based support employees to expand the U.S. commercial organization.
• Promote awareness of products to drive surgeon use through industry conferences, medical education symposia, direct training, webinars, and publishing additional clinical data.
• Increase digital marketing efforts to build brand awareness with event marketing engagement, targeted ads and emails, social media, and patient education.
• Drive utilization through existing Group Purchasing Organization (GPO) and Integrated Delivery Network (IDN) contracts and secure additional contracts.
• Continue to build upon clinical evidence of effectiveness and safety through ongoing BRAVO II and OPERA studies, and the collection of real-world quality improvement data on 1,100 patients.
• Evaluate and finalize the clinical study protocol for OviTex PRS in implant-based breast reconstruction to support a pre-market application for FDA approval.
• Advance the portfolio of reinforced tissue matrices with new product features and designs, including longer-acting resorbable polymers and lower-cost, higher-margin polymer-based devices.
• Explore additional technologies that may complement existing products or expand the number of products within the hernia, plastic and reconstruction, and broader soft-tissue reconstruction markets.
• Assess additional strategic partnerships with medical device companies for distribution, product development, and/or licensing agreements.
• Actively monitor the common stock's closing bid price and consider all available options to resolve the Nasdaq minimum bid price deficiency and regain compliance by September 14, 2026.
• Anticipate additional FDA interactions related to the OviTex PRS breast reconstruction study protocol.
• Intend to use the remaining proceeds from the Perceptive credit facility to fund operations and other general corporate purposes.
• May seek to sell common or preferred equity or debt securities or enter into a new credit facility if existing cash resources are insufficient to satisfy liquidity requirements.
• New pre-market requirements for medical devices will be put in place in Great Britain in 2026.

Key Dates

Recommendation

TELA Bio demonstrates solid revenue growth and promising clinical data for its OviTex products, indicating strong market acceptance and product efficacy. However, the company continues to incur significant net losses and faces a Nasdaq minimum bid price deficiency, which introduces considerable uncertainty and risk. The new debt facility provides liquidity but adds to indebtedness. Given the mixed financial performance and the immediate delisting risk, a 'hold' recommendation is appropriate for investors to monitor the company's ability to regain Nasdaq compliance and progress towards profitability, while acknowledging the underlying product strengths.

Keywords

TELA Bio, OviTex, OviTex PRS, Hernia Repair, Abdominal Wall Reconstruction, Plastic Surgery, Reconstructive Surgery, Medical Devices, Soft Tissue Reconstruction, Biologic Matrix, Polymer, FDA Clearance, SEC Filing, 10-K, Financial Results, Nasdaq, Debt Financing, Clinical Trials, Intellectual Property, Cybersecurity, Healthcare Regulation